# Genetic Link Between Cannabis Use and Psychosis Could Help Identify Those Most at Risk > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/genetic-risk-cannabis-psychosis-identify-high-risk-patients/ > **Published:** 2026-05-13T17:06:20-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:55:13-04:00 > **Clinical Summary:** Explore genetic risk cannabis psychosis to identify patients vulnerable to cannabis-induced psychosis for targeted counseling and risk assessment. --- ✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. Mental HealthResearchNeurologyTHCGeneticsRisk AssessmentPsychosis Why This Matters Clinicians can use emerging genetic risk profiles to identify patients at elevated vulnerability to [cannabis-induced psychosis](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/), enabling more targeted counseling and risk stratification during substance use assessments. This research supports personalized medicine approaches where patients with specific genetic markers might benefit from stronger warnings against [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) or closer psychiatric monitoring. Understanding the genetic architecture of cannabis-psychosis risk allows providers to move beyond one-size-fits-all prevention strategies and instead counsel patients based on individual biological susceptibility. Clinical Summary Recent genetic research from King’s College London has identified distinct and shared genetic vulnerabilities that increase the risk of psychosis in cannabis users, suggesting that some individuals carry inherent biological susceptibility to cannabis-induced psychiatric adverse effects. This work advances our understanding of the pharmacogenetics underlying [cannabis and psychosis](https://cedclinic.com/association-cannabis-glutamate-early-psychosis/), moving beyond the previous assumption that psychotic risk is uniform across all users. The findings have significant implications for clinical practice, as they suggest that future genetic screening could help identify high-risk patients before cannabis exposure, particularly important given the increasing availability of high-potency products and therapeutic uses of cannabis. Clinicians should consider obtaining detailed psychiatric and family histories to screen for genetic predisposition when counseling patients about [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) or considering it as a therapeutic option. These discoveries could eventually inform personalized medicine approaches and guide safer prescribing practices or patient counseling regarding the individualized risks of psychosis associated with cannabis consumption. Dr. Caplan’s Take “What this genetic research tells us clinically is that we can’t keep treating cannabis as a monolithic risk factor—some patients carry genetic variants that substantially increase their psychotic vulnerability, while others in the same exposure circumstances don’t develop illness, and that distinction matters enormously for our screening and counseling conversations.” Clinical Perspective Recent genetic studies identifying shared liability between [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and [psychosis risk](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) offer intriguing possibilities for stratified prevention, yet clinicians should interpret these findings cautiously when counseling patients. The genetic correlation does not establish causation, and the clinical utility of genetic risk scores remains unproven in real-world practice, where environmental, social, and developmental factors continue to play substantial roles in psychotic illness. Additionally, most identified genetic variants confer small individual effect sizes, and polygenic prediction in diverse populations remains scientifically challenging. Rather than awaiting genetic screening tools that may not soon materialize, clinicians can apply existing knowledge by taking thorough personal and family psychiatric histories before discussing cannabis with patients, particularly those with first-degree relatives affected by psychosis, and by reinforcing that cannabis use during adolescence and early adulthood carries documented psychosis risks regardless of genetic background. The genetic perspective should complement, not replace, standard risk assessment and [harm reduction](https://cedclinic.com/can-you-mix-weed-and-alcohol/) 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Genetic%20link%20between%20cannabis%20use%20and%20psychosis%20could%20help%20to%20identify%20those%20most%20at%20risk%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D52750)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D52750)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Genetic%20link%20between%20cannabis%20use%20and%20psychosis%20could%20help%20to%20identify%20those%20most%20at%20risk%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D52750)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Cannabis and Tobacco Combo Linked to Elevated Psychosis Risk in Vulnerable Individuals](https://cedclinic.com/cannabis-and-tobacco-combo-linked-to-elevated-psychosis-risk-in-vulnerable-individuals/) - [Cannabis and Psychosis Risk: How Legalization Could Impact Clinical Practice](https://cedclinic.com/cannabis-and-psychosis-risk-how-legalization-could-impact-clinical-practice/) - [Placenta May Hide Early Warning Signs of Schizophrenia Risk – ScienceAlert](https://cedclinic.com/placental-biology-prenatal-thc-exposure-schizophrenia-risk/) 📰 Source: [https://medicalxpress.com/news/2026-05-genetic-link-cannabis-psychosis.html](https://medicalxpress.com/news/2026-05-genetic-link-cannabis-psychosis.html) Further Reading Evidence Watch[Expert Panel Identifies Key Risk Factors for Cannabis Use in Rheumatology Patients](https://cedclinic.com/cannabis-risk-assessment-rheumatology/) CED Clinic Blog[Small Study Links Genetic Variant and Brain Protein Levels to Cannabis Drug Exposure—But Results Are Preliminary](https://cedclinic.com/comt-gene-variant-cannabis-plasma-study-2025/) Evidence Watch[Correlates and Predictors of Criminal Legal Involvement in People With First-Episode Psychosis.](https://cedclinic.com/criminal-legal-involvement-first-episode-psychosis/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Study identifies genetic pathways linking cannabis use and psychosis – News-Medical.Net](https://cedclinic.com/researchers-identify-genetic-pathways-linking-cannabis-use-disorder-and-psychosis-risk/) This study explores the genetic pathways that connect cannabis use with increased [psychosis risk](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/), providing deeper insight into biological vulnerabilities. [Read the Study](https://cedclinic.com/researchers-identify-genetic-pathways-linking-cannabis-use-disorder-and-psychosis-risk/) [Cannabis and Tobacco Combo Linked to Elevated Psychosis Risk in Vulnerable Individuals](https://cedclinic.com/cannabis-and-tobacco-combo-linked-to-elevated-psychosis-risk-in-vulnerable-individuals/) Learn how combining cannabis and tobacco use can increase psychosis risk, especially in genetically vulnerable populations. [Learn More](https://cedclinic.com/cannabis-and-tobacco-combo-linked-to-elevated-psychosis-risk-in-vulnerable-individuals/) [Teen Marijuana Use Doubles Chances of Future Psychotic Disorders, Study Finds](https://cedclinic.com/adolescent-cannabis-use-psychotic-risk-study/) Discover research showing how adolescent marijuana use significantly raises the risk of developing psychotic disorders later in life. [Explore Research](https://cedclinic.com/adolescent-cannabis-use-psychotic-risk-study/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).